• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-04-21

  This study reveals that naturally occurring angiotensin peptides, including Angiotensin 1/2 (1-6), significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor, suggesting a novel intersection between the renin-angiotensin system and viral pathogenesis. These findings have important implications for understanding COVID-19 infection mechanisms and designing targeted experimental protocols.

• Phosphatase Inhibitor Cocktail: Redefining Phosphorylation I

  2026-04-20

  Explore how the Phosphatase Inhibitor Cocktail (2 Tubes, 100X) advances protein phosphorylation preservation for regenerative medicine and translational assays. This article delivers a mechanistic deep dive and reference-driven guidance for high-fidelity sample preparation.

• Ouabain as a Selective Na⁺/K⁺-ATPase Inhibitor: Integrating

  2026-04-20

  Discover how Ouabain, a selective Na⁺/K⁺-ATPase inhibitor, enables precise ion transport manipulation and experimental control in cardiovascular and cell signaling research. This article uniquely bridges mechanistic depth with practical assay protocol decisions, leveraging recent innovations for robust translational workflows.

• Spider Toxin v-Agatoxin-IVA Reveals N-Type Calcium Channel B

  2026-04-19

  Sidach and Mintz’s study redefines the selectivity of v-Agatoxin-IVA, showing it blocks not only classic P-type but also N-type neuronal calcium channels at higher concentrations. These findings challenge established pharmacological classifications and inform the experimental use of channel blockers in neurophysiology and neurodegeneration research.

• USP42 Drives Breast Cancer Progression via JNK/p38 Apoptosis

  2026-04-18

  This study identifies USP42 as a key promoter of breast cancer progression by inhibiting apoptosis through the JNK/p38 MAPK pathway. The findings clarify USP42’s central role in breast tumor growth and highlight its potential as a therapeutic target.

• Torin2: mTOR Inhibitor Workflows for Cancer Research Success

  2026-04-17

  Torin2 stands out as a highly potent, selective mTOR inhibitor, enabling precision dissection of the PI3K/Akt/mTOR pathway in both cellular and in vivo cancer models. Discover how optimized protocols and troubleshooting strategies with Torin2 drive robust, reproducible apoptosis assays and tumor inhibition studies.

• VER 155008, HSP 70 Inhibitor: Data-Backed Tools for Cell Ass

  2026-04-16

  This article explores how VER 155008, HSP 70 inhibitor, adenosine-derived (SKU A4387) addresses key challenges in apoptosis and proliferation assays for cancer research. Drawing on published studies and validated workflow data, we outline best practices for protocol optimization, data reliability, and vendor selection. The focus is on practical, evidence-backed solutions that improve experimental reproducibility for biomedical researchers.

• NUAK1-Dependent Tau Ser356 Phosphorylation in Alzheimer’s Di

  2026-04-15

  This study elucidates the role of NUAK1-driven phosphorylation of tau at Ser356 in Alzheimer’s disease (AD) progression. It demonstrates that pharmacological inhibition using WZ4003 specifically reduces pathogenic p-tau Ser356 in human brain cultures, providing mechanistic insight for future therapeutic strategies.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody in High-Sensitivity D

  2026-04-14

  The Cy5 Goat Anti-Mouse IgG (H+L) Antibody enables robust, multiplexable, and ultra-sensitive detection of mouse IgG in advanced immunoassays. Leveraging Cy5 fluorescence and affinity purification, this APExBIO reagent is optimized for translational workflows, from immunocytochemistry to cutting-edge hybrid vaccine studies.

• Applied Protocols with Angiotensin I for Cardiovascular Rese

  2026-04-13

  Leverage Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) for precision cardiovascular and neuroendocrine workflows. This guide details advanced experimental protocols, optimization strategies, and troubleshooting tips—grounded in recent research and APExBIO’s rigorously characterized peptide—for maximized reproducibility and assay performance.

• TAI-1: Precision Hec1 Inhibitor Workflows for Cancer Researc

  2026-04-12

  TAI-1, a first-in-class Hec1 inhibitor, offers exceptionally potent and selective disruption of mitotic regulation, making it a transformative tool for oncology research. This guide details advanced workflows, troubleshooting strategies, and practical insights—empowering researchers to maximize TAI-1’s impact in cancer cell models.

• Mubritinib (TAK 165): Optimizing Complex I Inhibition Workfl

  2026-04-12

  Mubritinib (TAK 165) is redefining how researchers target mitochondrial complex I inhibition in drug-resistant cancers and select viral models. This article delivers actionable workflows, protocol enhancements, and troubleshooting strategies that leverage Mubritinib’s selectivity and robust in vitro/in vivo performance, with insights drawn from recent antiviral screening breakthroughs.

• Simvastatin (Zocor): Applied Workflows and Assay Optimizatio

  2026-04-11

  Simvastatin (Zocor) from APExBIO empowers researchers to probe cholesterol metabolism and apoptosis induction in hepatic cancer cells with reproducible, high-content results. This article integrates evidence-based workflows, troubleshooting advice, and machine learning–driven phenotypic profiling to maximize experimental success in cardiovascular and cancer biology.

• EPZ5676: Optimizing DOT1L Inhibitor Workflows for Leukemia R

  2026-04-11

  EPZ5676, a potent and selective DOT1L inhibitor, empowers researchers to dissect MLL-rearranged leukemia and histone methylation pathways with unprecedented precision. This guide details optimized experimental workflows, troubleshooting strategies, and actionable insights, drawing on cutting-edge studies and comparative resources.

• Mubritinib (TAK 165): Scenario-Driven Solutions for AML a...

  2026-04-10

  This article presents real-world laboratory scenarios where Mubritinib (TAK 165, SKU B1543) delivers reproducible, data-backed solutions for oxidative phosphorylation inhibition, apoptosis induction, and selective cytotoxicity in chemotherapy-resistant acute myeloid leukemia (AML) and primary effusion lymphoma (PEL) assays. Learn how APExBIO’s Mubritinib B1543 provides workflow reliability, protocol flexibility, and vendor assurance for advanced cancer and viral oncology research.

408 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page